865
Views
94
CrossRef citations to date
0
Altmetric
COGNITION

The Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen: A cross-sectional comparison of established screening tools in a German-Swiss population

, , , , , , , , , & show all
Pages 16-23 | Received 16 May 2014, Accepted 25 Aug 2014, Published online: 08 Oct 2014
 

Abstract

The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) has recently been developed as a fast and easy cognitive screening tool specifically designed for patients with motor impairments in routine clinical use. The German/Swiss-German version of the ECAS was validated in a German-Swiss consortium. One hundred and thirty-six non-demented ALS patients and 160 healthy controls were included in the study. In addition, the Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA) and Consortium to Establish a Registry for Alzheimer's Disease plus Scale (CERAD plus) were administered to subgroups of patients. Results showed that administration of ECAS was fast (mean 24 min). Similar to the population in the UK version, ALS patients performed significantly worse in the ALS-specific functions (p < 0.001), specifically in the domain of language (p < 0.001), verbal fluency (p = 0.005) and executive functions (p = 0.02), but not for the non-ALS-specific functions. Carers reported behavioural abnormalities in about 30% and psychotic symptoms in 6% of the patients. Compared to ECAS, FAB, MoCA and CERAD were more generic and performance was not adjusted to motor speed. We conclude that the German/Swiss-German version of the ECAS is a fast and easy to administer cognitive screening instrument sensitive for ALS-specific dysfunctions and behaviour change.

Acknowledgements

We thank the research nurses involved in the study: Bea Goldman and Ursula Schneider. We would particularly like to thank the patients and carers who graciously gave of their time to participate in the study. We also thank Maren Carbon for her help in the back-translation of the ECAS.

This is an EU Joint Programme – Neurodegenerative Disease Research (JPND) project. The project is supported through the following organizations under the aegis of JPND – e.g. Germany: Bundesministerium für Bildung und Forschung (BMBF, FKZ), Sweden: Vetenskaprådet Sverige, Poland: Narodowe Centrum Badań i Rozwoju (NCBR). This work was supported by the Deutsche Forschungsgemeinschaft and the BMBF and Schweizerischer Nationalfonds.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Supplementary material available online

Supplementary Tables I–V.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.